Skip to main content

Table 5 Adverse events after administration of one-shot CDDP via HAI and RT up to the time of the second response evaluation (median 4.3 month), as categorized by NCI-CTCAE v5.0

From: Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

  All (N = 32)
Adverse event Any grade Grade ≥ 3
Fever 25 (8) 0
Aspartate aminotransferase increased 16 (5) 0
Alanine aminotransferase increased 12 (4) 0
Anorexia 6 (2) 0
Elevated ammonia 6 (2) 0
Ascites 3 (1) 0
Fatigue 3 (1) 0
  1. The adverse events after administration of one-shot CDDP via HAI and RT up to time of the the second response evaluation (median 4.3 month), as categorized by NCI-CTCAE v5.0. Data are presented as percentages (numbers). CDDP cisplatin; HAI hepatic arterial infusion; RT radiation therapy; NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Event